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Abstract
Arfaptin2 contains a Bin/Amphiphysin/Rvs (BAR) domain and directly interacts with proteins of the Arf/Arl family in their
active GTP-bound state. It has been proposed that BAR domains are able to sense membrane curvature and to induce
membrane tubulation. We report here that active Arf1 is required for the recruitment of Arfaptin2 to artificial liposomes
mimicking the Golgi apparatus lipid composition. The Arf1-dependent recruitment of Arfaptin2 increases with membrane
curvature, while the recruitment of Arf1 itself is not sensitive to curvature. At high protein concentrations, the binding of
Arfaptin2 induces membrane tubulation. Finally, membrane-bound Arfaptin2 is released from the liposome when ArfGAP1
catalyzes the hydrolysis of GTP to GDP in Arf1. These results show that both Arf1 activation and high membrane curvature
are required for efficient recruitment of Arfaptin2 to membranes.
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Introduction
Arfaptin2 (also known as POR1) is a BAR (Bin/Amphiphysin/
Rvs) domain protein that was first identified as a Rac1-interacting
protein and as a class I Arf (Arf1, 3 and 5) effector, suggesting that
it plays an important role in the cross-talk between Arf and Rac-
mediated signalling pathways [1–4]. Later on, Arfaptin2 was
shown to interact with Arl1 (Arf-like protein 1) [5,6]. Arfaptin2 is
also a substrate of the Akt kinase and is involved in neuroprotec-
tion in Huntington disease, but whether this function is related to
the Arf/Rac pathways remains unclear [7,8].
Arfaptin2, like other BAR domain-containing proteins, is able
to sense membrane curvature and to tubulate liposomes in vitro [9–
12]. In vivo, Arfaptin2 is recruited on Golgi membranes by Arl1
and its overexpression induces the formation of tubular structures
emanating from the Golgi complex [13,14]. How BAR domain-
containing proteins sense membrane curvature and triggers
membrane deformation remains a matter of debate. It has been
proposed that the curvature sensing properties of BAR domains
are mediated by a higher density of binding sites on curved
membranes and not by an increase in the affinity of the protein for
the curved membranes [15,16]. Membrane deformation could be
induced by protein-protein crowding at the surface of a membrane,
as recently documented for epsin1 and AP180, two proteins
involved in the formation of clathrin-coated vesicles [17].
In this study, we have reconstituted Arf1-mediated binding of
Arfaptin2 on Large Unilamellar Vesicles (LUVs) and Giant
Unilamellar Vesicles (GUVs). We show that Arfaptin2 is recruited
by active Arf1 (GTP-bound) and preferentially associates to highly
curved membranes. We also provide evidence that Arfaptin2 can
trigger membrane tubulation only at high concentration.
Materials and Methods
Reagents
Lipids and biotinylated 1,2-Dioleoyl-sn-Glycero-3-Phosphoetha-
nolamine-N-(Cap Biotinyl) (Biot-CAP-DOPE) were purchased
from Avanti Polar Lipids. The fluorescent N-((4-(4, 4-difluoro-5-
(2-thienyl)-4-bora-3a, 4adiaza-s-indacene-3-yl) phenoxy) acetyl)
sphingosine (BODIPY-TR-ceramide, BodTRCer), N-(6-tetra-
methylrhodaminethiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-
3-phosphoethanolamine, triethylammonium salt (TRITC-DHPE)
and Alexa488-C5-Maleimide were from Invitrogen. ATP, GTP,
GDP and GTPcS were purchased from Roche Molecular
Biochemicals. Streptavidin was obtained from Pierce. The Ni-
NTA superflow column was from QIAGEN. All other chemicals
were purchased from Sigma Aldrich.
Protein Purification
Detailed protocols for Arf1 and ArfGAP1 purification have
been published previously in Manneville et al. [18] and Am-
broggio et al. [19]. The hexa-histidine tagged version of the
biotinylated kinesin 1 was purified as described by Thoresen and
Gelles [20].
For fluorescence experiments in cuvette, Arf1 tagged with hexa-
histidine (Arf1-H6) was purified following the protocols described
by Liu et al. [21] and Ha et al. [22]. Briefly, the sequence of Arf1
was cloned into a pET21b vector and expressed in BL21 bacteria.
Non-myristoylated and myristoylated Arf1 were co-purified using
a Ni-NTA affinity column. The myristoylated version was purified
from the non-myristoylated by FPLC using a HP-phenylsepharose
column.
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Full-length human Arfaptin2 was expressed as an N-terminal
His-tag fusion protein in Escherichia coli BL21 cells (Stratagene,
Agilent Technologies). The cDNA of Arfaptin2 was acquired from
Imagenes (Clone IRALp962G021Q), amplified by PCR incorpo-
rating the restriction sites Nde I (59; primer AAAAAACATAT-
GACGGACGGGATCCTAGG) and Xho I (39; primer
AAAAAACTCGAGTCACTGCTCCTCTAGCCAGG) and
cloned into a pET16b vector (Novagen). The protein was purified
using a Ni-NTA affinity column. The eluted protein (elution
buffer: 50 mM NaH2PO4, 300 mM NaCl, 300 mM Imidazole)
was then incubated with 1 mM DTT for 2 hrs. DTT was
eliminated using gel filtration and Alexa488 labelling was
conducted. The excess dye was eliminated by gel filtration using
20 mM Tris, 150 mM NaCl. The dye/protein ratio was around 2.
Finally, the protein (16 mM) was snap-frozen and stored at280uC.
Liposome Preparation
Large unilamellar vesicles (LUVs) of a lipid composition similar
to Golgi membranes (Golgi-mix: Egg-PC 50%, Liver-PE 19%,
Brain-PS 5%, Liver-PI 10% and Cholesterol 16%) were prepared
by sequential extrusion through polycarbonate filters of 200 nm,
100 nm, 50 nm and 30 nm pore size in HKM buffer (HEPES
50 mM, KAcetate 120 mM, MgCl2 1 mM) [23,24]. The final
lipid concentration obtained was 4mM. For the FRET experi-
ments 1% mole of fluorescent TRITC-DHPE was added to the
lipid mix.
Golgi-mix giant unilamellar vesicles (GUVs) containing 1%
mole of fluorescent BODIPY-TR-Ceramide (BodTRCer) and 1%
of Biot-CAP-PE were generated by the electroformation technique
on ITO (indium-tin-oxide) coverslides [25] in a sucrose solution
matching the osmolarity of the used buffers.
Flotation Experiments
Proteins (0.75 mM) and liposomes (0.75 mM) were incubated in
HKM buffer at room temperature for 20 min in a total volume of
150 ml. The suspension was adjusted to 30% sucrose by adding
and mixing 100 ml of a 75% w/v sucrose solution in HKM buffer.
The resulting high-sucrose suspension was overlaid with 200 ml
HKM containing 25% w/v sucrose and 50 ml HKM containing
no sucrose. The sample was centrifuged at 55000 r.p.m.
(240,000 g) in a Beckman swinging rotor (TLS 55) for 1 h. The
bottom (250 ml), middle (150 ml) and top (50 ml) fractions were
manually collected from the bottom using a Hamilton syringe and
analysed by SDS–PAGE before and after staining with Sypro
orange (Molecular Probes). Quantification was performed using
the ImageJ software. For each condition (GDP or GTP) the sum of
the band signal recovered in the bottom and top fractions was
taken as 100% (total protein mass).
Fluorescence Measurements of Arfaptin2 Recruitment to
TRITC-LUVs after Arf1 Activation
Measurements were performed in a cylindrical quartz cuvette
containing 0.5 mM Arf1-H6 (initially in the GDP-bound form),
0.5 mM Arfaptin2-Alexa488 and 0.5 mM sequentially extruded
Golgi-mix liposomes (containing 1% fluorescent TRITC-DHPE)
in HKM buffer. The suspension was stirred with a small magnetic
bar. Reagents were sequentially added from stock solutions using
automatic pipettes. The Alexa488 fluorescence emission was
excited at 492 nm and measured at 518 nm. Fluorescence
measurements were normalized by the value before GTP addition
(t = 500 s).
Arfaptin2 Recruitment to Golgi-mix Lipid Tubes and
GUVs
Lipid tubes were pulled from GUVs using the motor domain of
kinesin1 coupled with the bacterial biotin carrier protein as
described previously [19]. Briefly, after tube pulling, 1 to 3 mM
Arf1 (bound to GDP or GTPcS) and Arfaptin2-Alexa488 were
incubated with the liposome/tube networks. Confocal fluores-
cence micrographs were obtained using a Zeiss Meta 510 confocal
microscope. Analyses were performed using the ImageJ software.
Results and Discussion
Arfaptin2 is Recruited to LUVs by Arf1:GTP in a Curvature
Dependent Manner
To assess binding of Arfaptin2 to membranes of different
curvatures and the role of Arf1 activation, we used two
complementary assays: flotation on sucrose gradients and FRET.
These experiments were performed on LUVs (Large Unilamellar
Vesicles) of lipid composition mimicking that of the Golgi
apparatus [24,26]. For the flotation assay (Figures 1A and 1B),
LUVs sequentially extruded through filters with pore sizes ranging
from 200 nm to 30 nm were incubated with Arfaptin2 labelled
with Alexa488 (Arfaptin2-Alexa488) in the presence of Arf1:GDP or
Arf1:GTP. The suspension was then adjusted to a high sucrose
concentration and overlaid with cushions of decreasing sucrose
concentration. The bottom and top fractions were collected after
ultracentrifugation. The LUVs are recovered in the top fraction
[24,26]. If Arfaptin2 binds to the LUVs, it will also be recovered in
this fraction. When Arf1 was incubated with GDP, both Arf1 and
Arfaptin2 did not bind to the vesicles and remained in the bottom
fraction (Figures 1A and 1B). In contrast, when Arf1 was activated
after incubation with GTP, Arf1 was detected in the top fraction in
a similar amount regardless of the size of the vesicles. On the other
hand, the amount of Arfaptin2 recovered in the top fraction
increased with the curvature of the liposomes.
In the FRET assay, we monitored the binding of Arfaptin2-
Alexa488 to LUVs of different sizes containing the fluorescent lipid
TRITC-DHPE. If Arfaptin2 binds to the vesicles after Arf1
activation, a decrease in the fluorescent signal of Alexa488 should
be observed because of FRET between the TRITC and Alexa488
fluorophores. Experiments shown in Figure 1C confirmed the
observations from the flotation assay. After Arf1 activation, the
FRET signal increased with LUV curvature. Interestingly, the
binding of Arfaptin2-Alexa488 to TRITC-LUVs was reversible, as
the addition of a catalytic amount of ArfGAP1 (10 nM), which
induces the hydrolysis of GTP to GDP in Arf1, resulted in the
recovery of Alexa488 fluorescence. As previously reported [24], the
activity of ArfGAP1 was greater on high-curvature liposomes than
low-curvature liposomes.
Of note, the effect of membrane curvature on Arf1-mediated
Arfaptin2 binding was better detected in the FRET assay than in
the flotation assay. This could be due to the following reasons. In
the flotation assay, both bound and unbound proteins are detected
whereas the FRET assay only monitors membrane-bound
Arfaptin2. Protein precipitation may also occur during the
flotation assay that could contaminate the bottom fraction. Finally,
about 20% of Arfaptin2 is recovered in the top fraction even in the
presence of Arf1:GDP.
All together, the above data indicate that Arfaptin2 is sensitive
to membrane curvature when recruited by Arf1:GTP. The Arf1-
Arfaptin2 interaction is GTP-dependent and can be reversed upon
GTP hydrolysis.
Arfaptin2 Recruitment to Curved Membranes by Arf1
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Arfaptin2 is Preferentially Recruited on Membrane Tubes
after Interaction with Arf1:GTP
We next monitored the binding of Arfaptin2 to membranes that
displays flat and curved regions in continuity. This was achieved
by pulling membrane tubes from giant unilamellar vesicles (GUVs)
using molecular motors [19,27]. We previously found that
Arf1:GTP binding is only weakly sensitive to membrane curvature
and binds to both GUV (flat membrane) and tubes (curved
membrane) [19]. As shown in Figure 2 (A and B), Arfaptin2-
Alexa488 alone or in the presence of Arf1:GDP did not bind to
either GUV or tube membranes. In contrast, when Arf1 was
loaded with the non-hydrolysable analogue of GTP, GTPcS,
Arfaptin2-Alexa488 binding was observed in the tubular region,
but not on the GUV membrane (Figure 2C). The calculation of
the relative density of Arfaptin2 bound to GUV and tube
membranes (distribution ratio given by (Arfaptin2-Alexa488/
BodTRCer)tube/(Arfaptin2-Alexa
488/BodTRCer)GUV; see [19])
gave a value close to 20, indicating that Arfaptin2 preferentially
binds to tubular regions. These results confirm and extend those
obtained with LUVs: Arf1:GTP preferentially recruits Arfaptin2 to
highly curved membranes even under conditions where both
proteins could interact on flat membranes.
Arfaptin2 Induces Membrane Deformations When
Recruited by Arf1:GTP at High Concentration
It has been shown that Arfaptin2 can tubulate liposomes in vitro
[9] and induce the formation of membrane tubes when over-
expressed in cells [13]. Under our experimental conditions, no
Figure 1. The binding of Arfaptin2 to liposomes requires Arf1 activation and increases with membrane curvature. A. Flotation assay.
Arfaptin2 and Arf1:GDP (left) or Arf1:GTP (right) (0.75 mM) were co-incubated with Golgi-mix liposomes (0.75 mM lipids) extruded through filters with
pores of decreasing sizes (200 nm, 100 nm, 50 nm and 30 nm). The suspension was adjusted to 30% w/v sucrose and overlaid with two cushions of
decreasing sucrose density. After centrifugation, the top (liposomes) and bottom (unbound proteins) fractions were collected and analysed by SDS-
PAGE. Direct Alexa488 fluorescence (top panels) was observed before Sypro-orange staining (bottom panels). B. Protein quantification from the Sypro-
orange stained gels shown in A. The black bars correspond to Arfaptin2 and the white/black striped bars to Arf1. C. FRET assay. Arfaptin2-Alexa488
(0.5 mM) and myr-Arf1-H6 were mixed with Golgi-mix liposomes of various sizes containing 1 mol% TRITC-DHPE. At the indicated times, GTP
(0.1 mM), EDTA (2 mM), MgCl2 (2 mM) and ArfGAP1 (10 nM) were added. Alexa488 fluorescence was followed in real time. Arfaptin2 was recruited to
the membranes after Arf1 activation (GTP). Arfaptin2 recruitment increased as a function of membrane curvature.
doi:10.1371/journal.pone.0062963.g001
Arfaptin2 Recruitment to Curved Membranes by Arf1
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membrane deformation was observed on GUVs incubated with
Arf1:GTPcS and Arfaptin2-Alexa488 at concentrations below
1 mM (data not shown). However, tubular protrusions emerging
from the vesicles could be seen at higher concentration (3 mM) in
the presence of Arf1:GTP (Figure 3). As expected, no Arfaptin2
signal was detected on the GUV membrane, but only on tubular
extensions.
In conclusion, our work illustrates a dual mechanism for
recruiting Arfaptin-2 to liposomes: activation of Arf1 and
membrane curvature. How could this work? A likely explanation
is given by the recently solved crystal structure of the complex
between Arl1 and the Arfaptin2 BAR domain [14]. In this study,
Nakamura and coll. show that two Arl1 molecules bind to the edge
of the Arfaptin2 BAR domain, leaving the concave part of this
Figure 2. Arfaptin2 binds preferentially to membrane tubes connected to GUVs when Arf1 is in its active GTP-bound state.
Membrane tube networks were pulled from Golgi-mix GUVs containing 1% red fluorescent lipid BodTRCer and 1% biotinylated lipid Biot-CAP-PE by
a truncated biotinylated version of kinesin1. Tube networks (red panel) were incubated with (A) 1 mM Arfaptin2-Alexa488, (B) 1 mM Arfaptin2-Alexa488
and 1 mM Arf1:GDP, or (C) 1 mM Arfaptin2-Alexa488 and 1 mM Arf1:GTPcS. Arrows ending with a triangle point to highly curved membrane regions
(tubes) where Arfaptin2 is bound. Arrows ending with a circle point to weakly curved membrane regions (vesicles) where Arfaptin2 binding is not
detected. Scale bar: 10 mm.
doi:10.1371/journal.pone.0062963.g002
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domain free to interact with a curved membrane. To our
knowledge, no 3D structure of Arf1 in complex with Arfaptin2
is available. It has been proposed that Arf1 can compete for Rac1
binding to Arfaptin2 [4]. The Rac1-binding site is located in the
central region of the BAR crescent shape [4], which then would
weaken the above hypothesis. However, the results of Nakamura
and coll. suggest that, although one molecule of Rac1 and two
molecules of Arl1 cannot coexist on the Arfaptin2 BAR domain, it
is likely that one molecule of Rac1 and one molecule of Arf1 can
associate. It will then be important to investigate whether Arf1
binds to Arfaptin2 at the same sites as Arl1 and to perform
competitive binding experiments on membranes.
The exact biological function of the Arf1-Arfaptin2 interaction
is not known. Although Arf1 is present on Golgi membranes,
Arfaptin2 appears to be recruited on these membranes by Arl1,
but not by Arf1 [13]. In any case, our results point to a generic
mechanism that could be used by both Arf1 and Arl1 in the
formation of transport vesicles: Arfaptin2 is preferentially recruited
to the nascent vesicle (curved membrane) where it interacts with
other proteins involved in membrane deformation and/or fission.
Hydrolysis of GTP-bound Arl1/Arf1 could then promote its
dissociation.
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